Natco Pharma gets USFDA EIR on pharmacovigilance requirements
Telangana: Natco Pharma has informed in a BSE filing that the Company has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA).
In November, Natco Pharma informed of the successful completion of the USFDA inspection of the firm’s compliance with Pharmacovigilance requirements with zero observations.
"We bring to your notice that the Company is in receipt of the Establishment Inspection Report (EIR) from USFDA concluding the inspection as Closed," Natco Pharma stated.
Read also: Natco Pharma Pharmacovigilance department successfully completes USFDA inspection
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, Natco today has eight manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
Read also: Natco Pharma reports over 3-fold rise in net profit at Rs 212.7 crore in Q3
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.